Art. -Nr.: HY-B0739A

Citicoline sodium

(Synonyms: Cytidine diphosphate-choline sodium; CDP-Choline sodium; Cytidine 5'-diphosphocholine sodium)

4 Cited Publications

Kundenbewertung

Based on 4 publication(s) in Google Scholar

Citicoline sodium is an endogenous intermediate in the synthesis of phosphatidylcholine which is a component of cell membranes. Citicoline sodium inhibits reactive oxygen species (ROS) and apoptosis. Citicoline sodium can be used for neurological disease and hearing loss study.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.77%
CAS. Nr.: 33818-15-4
Formel: C₁₄H₂₅N₄NaO₁₁P₂
Molecular Weight:510.31

Speicherung:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Citicoline sodium Chemical Structure

CAS. Nr.: 33818-15-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (4)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

Microbial Metabolite

Human Endogenous Metabolite

Caspase-8

Caspase 3

Caspase-9

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen :

Alle Caspase Isoform-spezifische Produkte anzeigen :

In Vitro

Citicoline (1-100 μM, 24 h or 24 h before glutamate treatment) sodium increases rats retinal cells viability after glutamate-induced excitotoxicity, and has synergistic effects with Tramiprosate (Homotaurine) (HY-14602)^[1].
Citicoline (100 μM, 24 h before glutamate treatment and 30 min before HG treatment) sodium decreases proapoptotic effects associated with neuroretinal degeneration such as glutamate-induced excitotoxicity and high glucose (HG)-induced neurotoxicity, and has synergistic effects with Tramiprosate in rats retinal cells^[1].
Citicoline (100 μM, 36-48 h) sodium reduces apoptosis in mice cochlear hair cells (HCs) and HEI-OC-1 cells after Neomycin (HY-150520) exposure, decreases the mRNA level of pro-apoptotic factor and increases anti-apoptotic factor, suppresses proapoptotic protein expression^[2]^[3].
Citicoline (100 μM, 36-48 h) sodium attenuates oxidative stress in mice cochlear HCs and HEI-OC-1 cells after Neomycin injury^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

Rat retinal cells
Concentration:

1, 10, 100 μM
Incubation Time:

24 h or 24 h before glutamate treatment (100 μM)
Result:

Did not affect viability of primary retinal cultures.
Significantly increased cell viability after glutamate-induced excitotoxicity, and had synergistic effects with homotaurine.

Apoptosis Analysis^[1]

Cell Line:

Rat retinal cells
Concentration:

100 μM
Incubation Time:

24 h before glutamate treatment and 30 min before HG treatment
Result:

Reduced apoptosis induced by administration of glutamate and HG, and had synergistic effects with homotaurine.

Apoptosis Analysis^[3]

Cell Line:

HEI-OC-1, mice cochlear tissue
Concentration:

10 μM
Incubation Time:

36 or 48 h (pretreatment for 12 h and then treated with 10 mM neomycin together for 12 and 24 h in cochlear tissue and HEI-OC-1, respectively, then allowed to recover in culture medium for another 12
Result:

Showed significantly lower numbers of cleaved caspase 3-positive cells and TUNEL-positive cells than the neomycin-only group.
Significantly reduced the percentage of apoptosis.
The protein levels of cleaved caspase 3 were decreased compared with the Neomycin-only group.
Decreased the pro-apoptotic factor Bax, Casp3, Casp8, and Casp9, and increased anti-apoptotic factor Bcl-2 by qPT-PCR analysis.

In Vivo

Citicoline (500-1000 mg/kg; i.p.; 1 h before test) sodium produces an anticonvulsant effect in pentylenetetrazole induced convulsion in male C57Bl/6 mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male C57Bl/6 mice (23-27 g) (The solution of convulsant pentylenetetrazole (1%) was infused intravenously at a flow rate of 0.01 ml/sec.)^[2]
Dosage:

500, 1000 mg/kg
Administration:

Intraperitoneal injection (i.p.); 1 h before test
Result:

Increased the threshold of clonic seizures and tonic phase of seizures with lethal outcome in a dose of 500 mg/kg.
The anticonvulsant effect was most pronounced in a dose of 1000 mg/kg.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 33818-15-4
Appearance Solid
Molecular Weight 510.31
Formel C₁₄H₂₅N₄NaO₁₁P₂
Color White to off-white
SMILES

NC(C=CN1[C@H]2[C@H](O)[C@H](O)[C@@H](COP(OP(OCC[N+](C)(C)C)([O-])=O)(O[Na])=O)O2)=NC1=O
Synonyms

Cytidine diphosphate-choline sodium; CDP-Choline sodium; Cytidine 5'-diphosphocholine sodium
Structure Classification
- Alkaloids
- Other Alkaloids
Initial Source
- Plants
- other families
- Animals
- Microorganisms
- Endogenous metabolite
Widespread
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (4)

All Others

Sort by:

Journal Impact Factor

Nat Neurosci

Lipid-accumulated reactive astrocytes promote disease progression in epilepsy. [Abstract]

2023 Apr;26(4):542-554. PMID: 36941428

Citicoline sodium purchased from MedChemExpress. Usage Cited in: Nat Neurosci. 2023 Apr;26(4):542-554. [Abstract]

In vivo EEG and ex vivo MEA recordings of KA epileptic mice treated with CDP-choline (Citicoline: 100 mg/kg) or vehicle control.
Int J Biol Macromol

Structure-based discovery of dual-target inhibitors of the helicase from bagaza virus. [Abstract]

2025 Jan 5:139536. PMID: 39765299
bioRxiv

2025 April 09.
Patent

US20240269160A1.

Lösungsmittel & Löslichkeit

In Vitro:

H₂O : ≥ 100 mg/mL (195.96 mM)

DMSO : < 1 mg/mL (insoluble or slightly soluble)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9596 mL

9.7980 mL

19.5959 mL

5 mM

0.3919 mL

1.9596 mL

3.9192 mL

10 mM

0.1960 mL

0.9798 mL

1.9596 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 100 mg/mL (195.96 mM); Clear solution; Need ultrasonic

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Davinelli S, et al. Cytoprotective Effects of Citicoline and Homotaurine against Glutamate and High Glucose Neurotoxicity in Primary Cultured Retinal Cells. Oxid Med Cell Longev. 2017;2017:2825703. [Content Brief]

[2]. Karpova MN, et al. Increase of the seizure threshold in C57BL/6 mice after citicoline administration. Bull Exp Biol Med. 2015 Jan;158(3):315-7. [Content Brief]

[3]. Zhong Z, et al. Citicoline Protects Auditory Hair Cells Against Neomycin-Induced Damage. Front Cell Dev Biol. 2020 Aug 31;8:712. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O	1 mM	1.9596 mL	9.7980 mL	19.5959 mL	48.9898 mL
	5 mM	0.3919 mL	1.9596 mL	3.9192 mL	9.7980 mL
	10 mM	0.1960 mL	0.9798 mL	1.9596 mL	4.8990 mL
	15 mM	0.1306 mL	0.6532 mL	1.3064 mL	3.2660 mL
	20 mM	0.0980 mL	0.4899 mL	0.9798 mL	2.4495 mL
	25 mM	0.0784 mL	0.3919 mL	0.7838 mL	1.9596 mL
	30 mM	0.0653 mL	0.3266 mL	0.6532 mL	1.6330 mL
	40 mM	0.0490 mL	0.2449 mL	0.4899 mL	1.2247 mL
	50 mM	0.0392 mL	0.1960 mL	0.3919 mL	0.9798 mL
	60 mM	0.0327 mL	0.1633 mL	0.3266 mL	0.8165 mL
	80 mM	0.0245 mL	0.1225 mL	0.2449 mL	0.6124 mL
	100 mM	0.0196 mL	0.0980 mL	0.1960 mL	0.4899 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Citicoline sodium

4 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Citicoline sodium

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Human Endogenous Metabolite Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Covalent Screening Library

Oxygen Sensing Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Pyroptosis Compound Library

FDA Approved & Pharmacopeial Drug Library

Alkaloids Library

Microbial Metabolite Library

Neurodegenerative Disease-related Compound Library

Food-Sourced Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Protease Inhibitor Library

Animal-Sourced Natural Product Library

Cell Death Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Endogenous Metabolite Library

Mass Spectrometry Human Metabolite Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Citicoline sodium

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen

Alle Caspase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (4)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Citicoline sodium Related Classifications

Art. -Nr.: HY-B0739A